6月26日，强生盘中上涨3.1%，报253.11美元/股，成交额6.95亿美元。
消息面上，欧洲药品管理局人用药品委员会（CHMP）建议扩大Tecvayli联合达雷妥尤单抗用于治疗既往至少接受过一线治疗的复发或难治性多发性骨髓瘤成人患者的适应症。该推荐基于III期MajesTEC-3研究数据，结果显示接受teclistamab联合达雷妥尤单抗皮下注射的患者，疾病进展或死亡风险较标准治疗降低83.4%。同日，古根海姆将强生目标价由266美元上调至270美元，维持买入评级。
强生所在的制药行业中，礼来涨5.88%、默沙东涨2.44%、辉瑞涨2.4%、诺和诺德涨1.34%、诺华涨0.54%，板块整体表现偏暖。强生公司是医疗保健领域的全球领先企业，通过创新药物和医疗技术两大业务部门运营。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.